<DOC>
	<DOC>NCT00504426</DOC>
	<brief_summary>The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.</brief_summary>
	<brief_title>Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Patients who fulfill all of the following items Patients with primary osteoporosis Patients who have existing 14 vertebral fractures Patients with back pain persisting for one week or more Postmenopausal women between 46 and less than 80 years of age</criteria>
	<gender>Female</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>